AIMS: Outcomes of patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES) and bare metal stents (BMS) have not been evaluated separately for specific dual and triple antiplatelet agent use. The purpose of this meta-analysis was to determine whether triple antiplatelet therapy (combination of clopidogrel, aspirin and cilostazol) has any advantage in efficacy compared with standard dual antiplatelet therapy (aspirin and clopidogrel) in patients undergoing PCI. METHODS: Electronic and printed sources were searched till May 2008 for randomized controlled clinical trials (RCTs) of cilostazol in combination with aspirin and clopidogrel. Pooled weighted mean difference (WMD) and pooled odds ratio (OR) with 95% confidence intervals (CIs) were calculated. RESULTS: A total of four RCTs including 1457 patients with a median follow-up period of 6-9 months were included in the analysis. The rates of major adverse cardiac and/or cerebrovascular events (MACE/MACCE), stent thrombosis and bleeding were not significantly different between triple and dual antiplatelet therapy groups. Pooled analysis showed that cilostazol was associated with significantly decreased incidence of in segment restenosis (ISR) (OR 0.51, 95% CI 0.38, 0.68; P < 0.00001), increased minimum luminal diameter (MLD) (WMD 0.16, 95% CI 0.10, 0.22; P < 0.00001) for both DES and BMS and also individually. However, the rates of target vessel revascularization (OR 0.45, 95% CI 0.25, 0.83; P = 0.01 and late lumen loss (pooled WMD 0.14, 95% CI 0.2, 0.07; P = 0.001) were decreased significantly only in the DES group receiving triple therapy. CONCLUSIONS: Cilostazol appears to be effective in reducing the rates of ISR without any significant benefit for MACE/MACCE.
AIMS: Outcomes of patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES) and bare metal stents (BMS) have not been evaluated separately for specific dual and triple antiplatelet agent use. The purpose of this meta-analysis was to determine whether triple antiplatelet therapy (combination of clopidogrel, aspirin and cilostazol) has any advantage in efficacy compared with standard dual antiplatelet therapy (aspirin and clopidogrel) in patients undergoing PCI. METHODS: Electronic and printed sources were searched till May 2008 for randomized controlled clinical trials (RCTs) of cilostazol in combination with aspirin and clopidogrel. Pooled weighted mean difference (WMD) and pooled odds ratio (OR) with 95% confidence intervals (CIs) were calculated. RESULTS: A total of four RCTs including 1457 patients with a median follow-up period of 6-9 months were included in the analysis. The rates of major adverse cardiac and/or cerebrovascular events (MACE/MACCE), stent thrombosis and bleeding were not significantly different between triple and dual antiplatelet therapy groups. Pooled analysis showed that cilostazol was associated with significantly decreased incidence of in segment restenosis (ISR) (OR 0.51, 95% CI 0.38, 0.68; P < 0.00001), increased minimum luminal diameter (MLD) (WMD 0.16, 95% CI 0.10, 0.22; P < 0.00001) for both DES and BMS and also individually. However, the rates of target vessel revascularization (OR 0.45, 95% CI 0.25, 0.83; P = 0.01 and late lumen loss (pooled WMD 0.14, 95% CI 0.2, 0.07; P = 0.001) were decreased significantly only in the DES group receiving triple therapy. CONCLUSIONS:Cilostazol appears to be effective in reducing the rates of ISR without any significant benefit for MACE/MACCE.
Authors: Andrew T L Ong; Eugène P McFadden; Evelyn Regar; Peter P T de Jaegere; Ron T van Domburg; Patrick W Serruys Journal: J Am Coll Cardiol Date: 2005-06-21 Impact factor: 24.094
Authors: E Tsuchikane; A Fukuhara; T Kobayashi; M Kirino; K Yamasaki; T Kobayashi; M Izumi; S Otsuji; H Tateyama; M Sakurai; N Awata Journal: Circulation Date: 1999-07-06 Impact factor: 29.690
Authors: Anthony A Bavry; Dharam J Kumbhani; Thomas J Helton; Przemyslaw P Borek; Girish R Mood; Deepak L Bhatt Journal: Am J Med Date: 2006-12 Impact factor: 4.965
Authors: John S Douglas; David R Holmes; Dean J Kereiakes; Cindy L Grines; Elizabeth Block; Ziyad M B Ghazzal; Douglas C Morris; Henry Liberman; Karen Parker; Claudine Jurkovitz; Nancy Murrah; Jovonne Foster; Pamela Hyde; G B John Mancini; William S Weintraub Journal: Circulation Date: 2005-10-24 Impact factor: 29.690
Authors: Jose M Mostaza-Prieto; Luís Martín-Jadraque; Isidro López; Salvador Tranche; Carlos Lahoz; Manuel Taboada; Teresa Mantilla; Begoña Soler; Beatriz Monteiro; Miguel Angel Sanchez-Zamorano Journal: Am Heart J Date: 2006-12 Impact factor: 4.749
Authors: Giuseppe G L Biondi-Zoccai; Marzia Lotrionte; Matteo Anselmino; Claudio Moretti; Pierfrancesco Agostoni; Luca Testa; Antonio Abbate; John Cosgrave; Antonio Laudito; Gian Paolo Trevi; Imad Sheiban Journal: Am Heart J Date: 2008-02-19 Impact factor: 4.749
Authors: Y Kubota; K Kichikawa; H Uchida; M Maeda; K Nishimine; S Makutani; S Sakaguchi; T Yoshioka; H Ohishi; Y Kimura Journal: Invest Radiol Date: 1995-09 Impact factor: 6.016
Authors: Massimo Montalto; Italo Porto; Antonella Gallo; Claudia Camaioni; Roberta Della Bona; Antonio Grieco; Filippo Crea; Raffaele Landolfi Journal: Int J Vasc Med Date: 2011-08-11